Style | Citing Format |
---|---|
MLA | Azimi M, et al.. "Soluble Molecules in Intravenous Immunoglobulin: Benefits and Limitations." Expert Review of Clinical Immunology, vol. 12, no. 2, 2016, pp. 99-101. |
APA | Azimi M, Aghamohammadi A, Ochs HD, Rezaei N (2016). Soluble Molecules in Intravenous Immunoglobulin: Benefits and Limitations. Expert Review of Clinical Immunology, 12(2), 99-101. |
Chicago | Azimi M, Aghamohammadi A, Ochs HD, Rezaei N. "Soluble Molecules in Intravenous Immunoglobulin: Benefits and Limitations." Expert Review of Clinical Immunology 12, no. 2 (2016): 99-101. |
Harvard | Azimi M et al. (2016) 'Soluble Molecules in Intravenous Immunoglobulin: Benefits and Limitations', Expert Review of Clinical Immunology, 12(2), pp. 99-101. |
Vancouver | Azimi M, Aghamohammadi A, Ochs HD, Rezaei N. Soluble Molecules in Intravenous Immunoglobulin: Benefits and Limitations. Expert Review of Clinical Immunology. 2016;12(2):99-101. |
BibTex | @article{ author = {Azimi M and Aghamohammadi A and Ochs HD and Rezaei N}, title = {Soluble Molecules in Intravenous Immunoglobulin: Benefits and Limitations}, journal = {Expert Review of Clinical Immunology}, volume = {12}, number = {2}, pages = {99-101}, year = {2016} } |
RIS | TY - JOUR AU - Azimi M AU - Aghamohammadi A AU - Ochs HD AU - Rezaei N TI - Soluble Molecules in Intravenous Immunoglobulin: Benefits and Limitations JO - Expert Review of Clinical Immunology VL - 12 IS - 2 SP - 99 EP - 101 PY - 2016 ER - |